Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck

Slide locked Sign in to view

Slide schematic 5/5

diagram 1/1 image 1/1 list 1/1 paragraph 1/1 title 1/1

Components 5

timeline illustration bullet paragraph headline

Tools 1

Executive summary slide · 90%

list/bullet: Preferred target in large market: Vedolizumab is the preferred biologic in UC with >$5B in annual sales

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

timeline 100%

Visual timeline of upcoming catalysts at the bottom of the slide.

Find anything